Sichuan Province Trial Confirms Truscreen Technology

Monday 19th October 2020

• Second phase of national clinical trial in Sichuan Province reported outstanding results

• Conducted by China Obstetrics and Gynaecology Association (COGA) a peak gynaecology body in China.

• Trial conducted across 14 hospitals with 1,243 patients participating

• Both sensitivity and specificity targeting pre-cancerous and cancerous cervical cells performed in aggregate better than other screening methods (see below table)

Truscreen Group Limited (NZX: TRU ) (Truscreen or Company) is pleased to advise results from The China Obstetrics and Gynaecology Association (COGA) ongoing national clinical trial that will screen over 20,000 women in 100 top-tier public hospitals across 10 provinces in China. The COGA evaluation compares the TruScreen technology to Liquid Based Cytology (LBC), and HPV DNA testing (HPV) and targets a nationwide consensus on Truscreen technology application in China as the main outcome of this large-scale trial.

See the link below for more details:

Sichuan Province Trial Confirms Truscreen Technology

Source: Truscreen Group Limited

Comments from our readers

No comments yet